| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2012: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
|---|
| Outline of Final Research Achievements |
We have reported that hepatitis C virus transgenic mice (HCV Tg) caused continuous liver injury and developed hepatocellular carcinoma through the Cre/loxP switching system. In addition, we showed recombinant vaccinia viruses expressing HCV nonstructural protein (rVV-N25) could protect against the progression of chronic hepatitis by way of suppression of macrophages activation. We focused on the role of tissue macrophages for liver disease of the HCV Tg mice and examined characteristic features of macrophages following rVV-N25 treatment. rVV-N25 treatment suppressed cell number and cytokine production on macrophages in the liver. M2 macrophages contribute to the induction of chronic liver inflammation in HCV mouse models. In addition, rVV-N25 induced therapeutic effect on liver tissue due to suppressed macrophage recruitment and activation.
|
